๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Phase II study: The combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma

โœ Scribed by Creagan, E. T. ;Schutt, A. J. ;Long, H. J. ;Green, S. J.

Publisher
John Wiley and Sons
Year
1986
Tongue
English
Weight
208 KB
Volume
14
Category
Article
ISSN
0098-1532

No coin nor oath required. For personal study only.

โœฆ Synopsis

Thirty patients with disseminated malignant melanoma received the combination DTIC, BCNU, actinomycin D, and vincristine. The objective response rate was 17 percent concornitant with moderate-to-severe nausea and vomiting in 80 percent of patients. Hematologic toxicity was transient. In the dose and schedule that we used, the four-drug regimen does not offer meaningful benefit for patients with advanced melanoma.

๐Ÿ“œ SIMILAR VOLUMES

Recombinant interferon alfa-2a in advanc
Recombinant interferon alfa-2a in advanced malignant melanoma. a phase i-ii study in combination with dtic
โœ G. R. C. McLeod; D. B. Thomson; P. Hersey ๐Ÿ“‚ Article ๐Ÿ“… 1987 ๐Ÿ› John Wiley and Sons ๐ŸŒ French โš– 384 KB

There is a rising incidence of malignant melanoma world-wide and, despite major improvements in i t s early diagnosis and treatment, the 10-year death rate remains at 20-25%. Evidence that the immune system has a role in the control of melanoma growth has encouraged immunological intervention. The r